SynthesisDrugs2022

Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases.

Tian Li et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 61,704 people · 2022

Randomised comparison

Reduced cardiovascular events

−10%−13% to −6%

Bigger than 1 in 10 for cardiovascular events

As reported

HR 0.90, 95% CI 0.87–0.94

Randomised comparison

Reduced deaths

−10%−17% to −2%

Bigger than 3 in 10 for all-cause mortality

As reported

HR 0.90, 95% CI 0.83–0.98 · the paper's word: All-cause mortality

Randomised comparison

Reduced cardiovascular events

−11%−15% to −6%

Bigger than 2 in 10 for cardiovascular events

As reported

HR 0.89, 95% CI 0.85–0.94

Randomised comparison

Reduced cardiovascular events

−21%−36% to −2%

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.79, 95% CI 0.64–0.98

Four numbers in the abstract

the abstract, start to end

… a reduction in all-cause mortality (HR: 0.90; 95% CI 0.83, 0.98; p = 0.01), cardiovascular mortality (HR: 0.89; 95% CI 0.85, 0.94; p < 0.0001), incidence of coronary revascularisation (HR: 0.79; 95% CI 0.64, 0.98; p = 0.03), and heart failure (HR: 0.90; 95% CI 0.87, 0.94; p < 0.0001) …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.900.87–0.94

All-cause mortality

HR 0.900.83–0.98

Cardiovascular events

HR 0.890.85–0.94

Cardiovascular events

HR 0.790.64–0.98

MetforminCardiovascular eventsAll-cause mortality

1 / 3

25 papers cite it

2022

2023

2024

2025

2026

this paperpooled itcites it

Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases.

What the trial testedrandomised · 61,704 people · 2022

Reduced cardiovascular events

Reduced deaths

Reduced cardiovascular events

Reduced cardiovascular events

Four numbers in the abstract

Where each one falls

Where it lands on the map

25 papers cite it